source
- Roivant's autoimmune drug brepocitinib succeeds in two pivotal trials, paving way for 2027 filingRoivant Sciences said its autoimmune drug brepocitinib met primary goals in two pivotal studies. The trials, which evaluated the drug in separate autoimmune indications, showed statistically signi…
- Lilly advances retatrutide toward sleep-apnea marketEli Lilly is moving its triple-agonist drug retatrutide closer to a potential launch for sleep-apnea. The company, which expects to introduce the drug for obesity next year, is now gathering data i…